{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,20]],"date-time":"2026-01-20T16:33:08Z","timestamp":1768926788670,"version":"3.49.0"},"reference-count":24,"publisher":"Oceanside Publications Inc.","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["allergy asthma proc"],"published-print":{"date-parts":[[2021,9,1]]},"abstract":"<jats:p><jats:bold>Background:<\/jats:bold>Crisaborole is a nonsteroidal anti-inflammatory phosphodiesterase 4 inhibitor that is approved for the treatment of patients with mild-to-moderate atopic dermatitis (AD); however, the efficacy and safety of crisaborole in patients with AD and other atopic comorbidities have not been investigated.<jats:bold>Objective:<\/jats:bold>This<jats:italic>post hoc<\/jats:italic>pooled analysis of the pivotal phase III studies (CrisADe CORE 1 and CORE 2) assessed the efficacy and safety of crisaborole versus vehicle in patients aged \u2265 2 years with mild-to-moderate AD and other atopic comorbidities.<jats:bold>Methods:<\/jats:bold>Patients with mild-to-moderate AD and a medical history of asthma, allergic rhinitis, or food allergies were identified. Efficacy assessments included the proportion of patients who achieved Investigator's Static Global Assessment (ISGA) success at day 29, ISGA clear or almost clear at day 29, and improvement in the Severity of Pruritus Scale score at week 4. Safety was assessed<jats:italic>via<\/jats:italic>treatment-emergent adverse events (TEAEs).<jats:bold>Results:<\/jats:bold>This analysis included 1522 patients (crisaborole, 1016; vehicle, 506); 26.2, 15.9, and 16.5% had a medical history of asthma, allergic rhinitis, and food allergies, respectively. The mean age was 12.2 years. A significantly greater proportion of patients treated with crisaborole achieved ISGA success at day 29 compared with patients treated with vehicle for most subgroups analyzed. Furthermore, a significantly greater proportion of patients treated with crisaborole achieved ISGA clear or almost clear at day 29 across all subgroups and demonstrated improvement in the Severity of Pruritus Scale score at week 4 versus patients treated with vehicle in most of the subgroups. Overall, most TEAEs were mild or moderate in severity; the most common treatment-related TEAE in patients with atopic comorbidities was application-site pain (crisaborole, 5.1%; vehicle, 1.7%).<jats:bold>Conclusion:<\/jats:bold>Crisaborole was efficacious and well tolerated in patients with mild-to-moderate AD and other atopic comorbidities, which suggested that crisaborole should be considered for the management of AD in this population. Clinical Trials NCT02118766 (CrisADe CORE 1) and NCT02118792 (CrisADe CORE 2), &lt;ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/www.clinicaltrials.gov\"&gt;www.clinicaltrials.gov&lt;\/ext-link&gt;<\/jats:p>","DOI":"10.2500\/aap.2021.42.210064","type":"journal-article","created":{"date-parts":[[2021,9,6]],"date-time":"2021-09-06T16:52:36Z","timestamp":1630947156000},"page":"425-431","source":"Crossref","is-referenced-by-count":9,"title":["Efficacy and safety of crisaborole in patients with mild-to-moderate atopic dermatitis and other atopic comorbidities"],"prefix":"10.2500","volume":"42","author":[{"given":"Jonathan M.","family":"Spergel","sequence":"first","affiliation":[{"name":"From the Division of Allergy and Immunology, Department of Pediatrics, Children's Hospital of Philadelphia, Perelman School of Medicine at University of Pennsylvania, Philadelphia, Pennsylvania;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael S.","family":"Blaiss","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Medical College of Georgia at Augusta University, Augusta, Georgia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Lio","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, Illinois;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aharon","family":"Kessel","sequence":"additional","affiliation":[{"name":"Division of Allergy and Clinical Immunology, Bnai Zion Medical Center, Haifa, Israel;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wendy C.","family":"Cantrell","sequence":"additional","affiliation":[{"name":"Village Dermatology, Birmingham, Alabama;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liza","family":"Takiya","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John L.","family":"Werth","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael A.","family":"O'Connell","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chuanbo","family":"Zang","sequence":"additional","affiliation":[{"name":"Medical Affairs, Pfizer Inc., Collegeville, Pennsylvania; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael J.","family":"Cork","sequence":"additional","affiliation":[{"name":"Department of Infection, Immunity, and Cardiovascular Disease, Sheffield Dermatology Research, University of Sheffield, Sheffield Children's Hospital, Sheffield, United Kingdom"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1355","reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1016\/j.jaci.2009.10.009","article-title":"Global variations in prevalence of eczema symptoms in children from ISAAC phase three","volume":"124","author":"Odhiambo","year":"2009","journal-title":"J Allergy Clin Immunol"},{"key":"B2","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1016\/j.clindermatol.2018.05.007","article-title":"Epidemiology of adult atopic dermatitis","volume":"36","author":"Sacotte","year":"2018","journal-title":"Clin Dermatol"},{"key":"B3","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.det.2017.02.002","article-title":"Public health burden and epidemiology of atopic dermatitis","volume":"35","author":"Silverberg","year":"2017","journal-title":"Dermatol Clin"},{"key":"B4","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/jid.2010.251","article-title":"Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health","volume":"131","author":"Shaw","year":"2011","journal-title":"J Invest Dermatol"},{"key":"B5","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1016\/j.jid.2018.08.028","article-title":"Atopic dermatitis in America study: a cross-sectional study examining the prevalence and disease burden of atopic dermatitis in the US adult population","volume":"139","author":"Chiesa Fuxench","year":"2019","journal-title":"J Invest Dermatol"},{"key":"B6","first-page":"12","article-title":"Treatment options and new therapeutic approaches in atopic dermatitis","author":"Boguniewicz","year":"2003","journal-title":"Dermatol Nurs"},{"key":"B7","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.jaci.2018.11.006","article-title":"The atopic march and atopic multimorbidity: many trajectories, many pathways","volume":"143","author":"Paller","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B8","doi-asserted-by":"crossref","first-page":"433","DOI":"10.2500\/aap.2019.40.4265","article-title":"Atopic dermatitis","volume":"40","author":"Peters","year":"2019","journal-title":"Allergy Asthma Proc"},{"key":"B9","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.anai.2019.04.020","article-title":"Comorbidities and the impact of atopic dermatitis","volume":"123","author":"Silverberg","year":"2019","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B10","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.jaci.2012.12.672","article-title":"Atopic dermatitis: a practice parameter update 2012","volume":"131","author":"Schneider","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"B11","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"B12","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.anai.2017.10.039","article-title":"Atopic dermatitis yardstick: practical recommendations for an evolving therapeutic landscape","volume":"120","author":"Boguniewicz","year":"2018","journal-title":"Ann Allergy Asthma Immunol"},{"key":"B13","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1016\/j.clindermatol.2017.03.008","article-title":"Selected comorbidities of atopic dermatitis: atopy, neuropsychiatric, and musculoskeletal disorders","volume":"35","author":"Silverberg","year":"2017","journal-title":"Clin Dermatol"},{"key":"B14","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1111\/pai.12095","article-title":"Association between severe eczema in children and multiple comorbid conditions and increased healthcare utilization","volume":"24","author":"Silverberg","year":"2013","journal-title":"Pediatr Allergy Immunol"},{"key":"B15","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.jaci.2014.10.012","article-title":"Respiratory allergy caused by house dust mites: what do we really know?","volume":"136","author":"Calder\u00f3n","year":"2015","journal-title":"J Allergy Clin Immunol"},{"key":"B16","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.imbio.2017.10.035","article-title":"House dust mite allergy: its innate immune response and immunotherapy","volume":"223","author":"Huang","year":"2018","journal-title":"Immunobiology"},{"key":"B17","volume-title":"Eucrisa [prescribing information]","year":"2020"},{"key":"B18","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1016\/j.jaci.2019.06.047","article-title":"Crisaborole and atopic dermatitis skin biomarkers: an intrapatient randomized trial","volume":"144","author":"Bissonnette","year":"2019","journal-title":"J Allergy Clin Immunol"},{"key":"B19","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1016\/j.jaad.2016.05.046","article-title":"Efficacy and safety of crisaborole ointment, a novel, nonsteroidal phosphodiesterase 4 (PDE4) inhibitor for the topical treatment of atopic dermatitis (AD) in children and adults","volume":"75","author":"Paller","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"B20","doi-asserted-by":"crossref","first-page":"44","DOI":"10.2340\/00015555924447","article-title":"Diagnostic features of atopic dermatitis","volume":"92","author":"Hanifin","year":"1980","journal-title":"Acta Derm Venereol"},{"key":"B21","first-page":"e13","article-title":"Assessment of pruritus in atopic dermatitis: validation of the Severity of Pruritus Scale (SPS)","volume":"3","author":"Yosipovitch","year":"2018","journal-title":"ltch"},{"key":"B22","article-title":"Introductory Guide MedDRA version 19.1","year":"2016"},{"key":"B23","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.jaad.2017.06.010","article-title":"Long-term safety of crisaborole ointment 2% in children and adults with mild to moderate atopic dermatitis","volume":"77","author":"Eichenfield","year":"2017","journal-title":"J Am Acad Dermatol"},{"key":"B24","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1007\/s40257-020-00510-6","article-title":"Safety, effectiveness, and pharmacokinetics of crisaborole in infants aged 3 to < 24 months with mild-to-moderate atopic dermatitis: a phase IV open-label study (CrisADe CARE 1)","volume":"21","author":"Schlessinger","year":"2020","journal-title":"Am J Clin Dermatol"}],"container-title":["Allergy and Asthma Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ingentaconnect.com\/content\/ocean\/aap\/2021\/00000042\/00000005\/art00014","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,8]],"date-time":"2023-11-08T11:32:31Z","timestamp":1699443151000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ingentaconnect.com\/content\/10.2500\/aap.2021.42.210064"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,1]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2021,9,1]]}},"alternative-id":["1088-5412(20210901)42:5L.425;1-"],"URL":"https:\/\/doi.org\/10.2500\/aap.2021.42.210064","relation":{},"ISSN":["1088-5412"],"issn-type":[{"value":"1088-5412","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9,1]]}}}